Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Conditions:   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Small Cell Neuroendocrine Carcinoma;   Small Cell Neuroendocrine Carcinoma
    Interventions:   Biological: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  2. Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:   Drug: 68-Gallium DOTATATE
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  3. Condition:   High Grade Neuroendocrine Neoplasms
    Interventions:   Drug: Cabozantinib;   Procedure: Blood for plasma biomarkers;   Procedure: Tissue biopsy
    Sponsors:   Washington University School of Medicine;   Exelixis
    Recruiting
  4. Conditions:   Neuroendocrine Tumors;   Liver Metastases
    Intervention:   Radiation: TheraSpheres Selective Internal Radiation Therapy (SIRT)
    Sponsors:   Imperial College London;   Biocompatibles UK Ltd, a BT International group company
    Recruiting
  5. Conditions:   Neuroendocrine Tumors;   Neuroendocrine Tumor Grade 3;   Neuroendocrine Carcinoma;   Neuroendocrine Neoplasm
    Interventions:   Drug: Chidamide;   Drug: Sintilimab
    Sponsors:   Peking Union Medical College Hospital;   The First Affiliated Hospital of Xiamen University;   Harbin Medical University
    Recruiting
  6. Conditions:   Metastatic Malignant Neoplasm in the Liver;   Neuroendocrine Neoplasm
    Interventions:   Procedure: Arterial Embolization;   Biological: Pembrolizumab;   Biological: Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate;   Device: Yttrium-90 Microsphere Radioembolization
    Sponsors:   Nicholas Fidelman, MD;   Merck Sharp & Dohme Corp.;   BTG International Inc.
    Recruiting
  7. Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor
    Intervention:   Drug: Belzutifan
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  8. Conditions:   Small Cell Neuroendocrine Carcinoma;   Prostate Cancer;   Small Cell Carcinoma
    Interventions:   Drug: Apalutamide;   Biological: Cetrelimab
    Sponsors:   Rahul Aggarwal;   Janssen Scientific Affairs, LLC
    Not yet recruiting
  9. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  10. Condition:   Advanced or Metastatic EP-NEC
    Interventions:   Drug: Camrelizumab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Apatinib
    Sponsor:   Huazhong University of Science and Technology
    Not yet recruiting
  11. Conditions:   Neuroendocrine Tumours;   Neuroendocrine Tumour of the Lung;   Small Intestinal NET
    Intervention:   Drug: Surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Recruiting
  12. Conditions:   Neuroendocrine Tumor;   Liver Metastases;   Neuroendocrine Gastroenteropancreatic Tumour
    Interventions:   Procedure: Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection;   Procedure: Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection;   Drug: LUTATHERA® by intra-arterial hepatic (IAH) injection;   Procedure: Scan
    Sponsors:   University Hospital, Bordeaux;   Advanced Accelerator Applications
    Recruiting
  13. Conditions:   Neuroendocrine Tumors;   Progesterone Receptor Positive Tumor;   Estrogen Receptor Positive Tumor
    Intervention:   Drug: Tamoxifen 20 mg
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting
  14. Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  15. Conditions:   SCLC;   Small Cell Cancer;   Advanced Solid Tumor;   High Grade Neuroendocrine Cancers
    Interventions:   Drug: Lurbinectedin;   Drug: Berzosertib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  16. Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  17. Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Urothelial Carcinoma;   Large Cell Neuroendocrine Carcinoma of the Lung;   Homologous Recombination Deficiency
    Intervention:   Drug: Lurbinectedin
    Sponsor:   Jazz Pharmaceuticals
    Not yet recruiting
  18. Conditions:   Bile Duct Cancer;   Gall Bladder Cancer;   Breast Cancer;   Neuroendocrine Tumors;   Ovarian Cancer;   Pancreatic Adenocarcinoma;   Soft Tissue Sarcoma;   Vulvar Cancer;   Prostate Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Tivozanib
    Sponsors:   University of Florida;   Genentech, Inc.;   Aveo Oncology Pharmaceuticals
    Recruiting
  19. Conditions:   Bladder Small Cell Neuroendocrine Carcinoma;   Extensive Stage Lung Small Cell Carcinoma;   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Limited Stage Lung Small Cell Carcinoma;   Platinum-Resistant Lung Small Cell Carcinoma;   Platinum-Sensitive Lung Small Cell Carcinoma;   Prostate Small Cell Neuroendocrine Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Berzosertib;   Drug: Topotecan Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  20. Conditions:   Neuroendocrine Tumors;   Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Gastroenteropancreatic Neuroendocrine Tumor;   Vipoma;   Insulinoma;   Gastrinoma
    Intervention:   Drug: 177Lu-DOTATOC
    Sponsor:   British Columbia Cancer Agency
    Not yet recruiting
  21. Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  22. Condition:   NASH - Nonalcoholic Steatohepatitis
    Interventions:   Drug: Estradiol patch;   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Recruiting
  23. Conditions:   Lung Atypical Carcinoid Tumor;   Lung Neuroendocrine Neoplasm;   Lung Non-Small Cell Squamous Carcinoma;   Minimally Invasive Lung Adenocarcinoma;   Neuroendocrine Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Large Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting
  24. Conditions:   Castration-Resistant Prostate Carcinoma;   Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Prostate Adenocarcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Erdafitinib
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting
  25. Conditions:   Appendix Carcinoma;   Colon Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Malignant Digestive System Neoplasm;   Pancreatic Carcinoma;   Rectal Carcinoma;   Small Intestinal Carcinoma;   Anal Carcinoma;   Digestive System Carcinoma;   Digestive System Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor
    Interventions:   Procedure: Acupuncture Therapy;   Procedure: Acupressure Therapy;   Procedure: Oral Cryotherapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   The Safeway Foundation
    Recruiting
  26. Conditions:   Colorectal Cancer Not MSI-H or MMR-deficient;   GIST;   Oesophageal or Gastric Carcinoma;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Soft-tissue Sarcoma;   Thyroid Cancer;   Gastro-enteropancreatic Neuroendocrine Tumor;   Non-small Cell Lung Cancer;   Solid Tumor, Adult
    Interventions:   Drug: Phase 1 : Regorafenib;   Drug: Phase 1 : Avelumab;   Drug: Phase 2 : Regorafenib;   Drug: Phase 2 : Avelumab;   Drug: Phase 2: low-dose Regorafenib
    Sponsors:   Institut Bergonié;   Bayer;   Merck KGaA, Darmstadt, Germany
    Recruiting
  27. Conditions:   RET-altered Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   RET-altered Papillary Thyroid Cancer;   RET-altered Colon Cancer;   RET-altered Solid Tumors;   Lung Neoplasm;   Carcinoma, Non-Small-Cell Lung;   Thyroid Diseases;   Thyroid Neoplasm;   Thyroid Cancer, Papillary;   Carcinoma, Neuroendocrine;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms by Site;   Neoplasms;   Lung Diseases;   Respiratory Tract Disease;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Endocrine System Diseases;   Endocrine Gland Neoplasm;   Head and Neck Neoplasms;   Adenocarcinoma, Papillary;   Adenocarcinoma;   Carcinoma;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Neuroendocrine Tumors;   Neuroectodermal Tumors;   Neoplasms, Germ Cell and Embryonal;   Neoplasms, Nerve Tissue;   Colonic Neoplasms;   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasm;   Digestive System Disease;   Gastrointestinal Disease;   Colonic Diseases;   Intestinal Disease
    Intervention:   Drug: pralsetinib (BLU-667)
    Sponsor:   Hoffmann-La Roche
    Recruiting
  28. Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  29. Conditions:   Advanced Solid Tumors;   Glioblastoma;   Soft Tissue Sarcoma (Excluding GIST);   Endometrial Carcinoma;   Epithelial Ovarian Carcinoma;   Mesothelioma;   Gastroenteropancreatic Neuroendocrine Tumor;   SCLC;   Gastric Carcinoma;   Pancreatic Adenocarcinoma;   Colorectal Carcinoma;   Neuroendocrine Tumors
    Interventions:   Drug: Lurbinectedin;   Drug: Irinotecan
    Sponsor:   PharmaMar
    Recruiting
  30. Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting
  31. Condition:   Metastatic Castration-Resistant Prostate Cancer
    Interventions:   Combination Product: XmAb20717 + carboplatin + cabazitaxel;   Combination Product: XmAb20717 + olaparib;   Biological: XmAb20717 monotherapy
    Sponsor:   Xencor, Inc.
    Recruiting
  32. Condition:   Small-cell Lung Cancer
    Intervention:   Drug: HPN328
    Sponsor:   Harpoon Therapeutics
    Recruiting
  33. Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  34. Condition:   Metastatic Castration-Resistant Prostate Cancer
    Interventions:   Biological: Pembrolizumab 200 mg;   Drug: Olaparib 400 mg;   Drug: Docetaxel 75 mg/m^2;   Drug: Prednisone 5 mg;   Drug: Enzalutamide 160 mg;   Other: Dexamethasone 8 mg;   Drug: Olaparib 300 mg;   Drug: Abiraterone acetate 1000 mg;   Drug: Lenvatinib;   Biological: Pembrolizumab/Vibostolimab coformulation;   Drug: Carboplatin;   Drug: Etoposide
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  35. Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  36. Conditions:   Stage III Merkel Cell Carcinoma AJCC v8;   Stage IIIB Merkel Cell Carcinoma AJCC v8;   Stage IIIA Merkel Cell Carcinoma AJCC v8
    Interventions:   Drug: Avelumab;   Other: Peripheral Blood Collection;   Other: Placebo
    Sponsors:   University of Washington;   EMD Serono
    Recruiting
  37. Conditions:   Merkel Cell Carcinoma;   Skin Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting
  38. Condition:   Neurofibromatosis Type 2
    Interventions:   Drug: REC-2282;   Drug: Placebo
    Sponsor:   Recursion Pharmaceuticals Inc.
    Not yet recruiting
  39. Conditions:   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of the Lung;   Merkel Cell Carcinoma;   Liposarcoma
    Intervention:   Biological: CAR-GPC3 T Cells
    Sponsors:   SOTIO, LLC;   SOTIO Biotech
    Not yet recruiting
  40. Condition:   Advanced or Metastatic Paraganglioma/ Pheochromocytoma
    Intervention:   Drug: Anlotinib
    Sponsor:   Nanjing First Hospital, Nanjing Medical University
    Recruiting
  41. Conditions:   Paraganglioma;   Pheochromocytoma
    Intervention:   Drug: Lanreotide
    Sponsors:   Antonio Fojo;   Ipsen
    Recruiting